CLINICOECONOMIC ANALYSIS OF THE USE OF MARAVIROC VERSUS OTHER RESERVE DRUGS IN PATIENTS WHO HAVE EXPERIENCED ANTIRETROVIRAL THERAPY FOR HIV INFECTION
- Authors: PYADUSHKINA E.A.1, GORYAYNOV S.V1, OMELYANOVSKY V.V2, AVXENTYEVA M.V2,3, REBROVA O.Y.1,4
-
Affiliations:
- National Center for Health Technology Assessment
- Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
- Issue: No 5 (2013)
- Pages: 59-67
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/277100
- ID: 277100
Cite item
Abstract
Full Text
About the authors
Elena A. PYADUSHKINA
National Center for Health Technology Assessment
Email: epyadushkina@mail.ru
S. V GORYAYNOV
National Center for Health Technology Assessment
Email: ocdp@inbox.ru
V. V OMELYANOVSKY
Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration
Email: vvo@hta-rus.ru
M. V AVXENTYEVA
Center for Health Technology Assessment, Russian Presidential Academy of National Economy and Public Administration; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: avksent@yahoo.com
O. YU REBROVA
National Center for Health Technology Assessment; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Email: o.yu.rebrova@gmail.com
References
- Количество ВИЧ-инфицированных в России за 2012 г. (Предварительные данные по состоянию на 22.11.2012 г.). Статистика Федерального центра СПИДа. http:// www.hivrussia.ru/stat/2012-3.shtml.
- Patient evaluation and antiretroviral treatment for adults and adolescents. HIV/AIDS treatment and care. Clinical protocols for the WHO European Region. 2012 Revisions. http://www.euro.who.int/data/assets/pdf_file/0012/152013/ e95794.pdf
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю. и др. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2012; 6(приложение). 28 с.
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Ермак Т.Н. и др. Протоколы лечения больных ВИЧ-инфекцией. Рекомендации Федерального научно-методического Центра по профилактике и борьбе со СПИДом по применению антиретровирусных препаратов. Эпидемиол. инфекц. болезни. Актуал. вопр.2011; 3 (приложение). 24 с.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. (Last updated February 12, 2013; last reviewed February 12, 2013). http://aidsinfo.nih.gov/contentfiles/lvguidelines/ adultandadolescentgl.pdf.
- Antiretroviral Treatment of Adult HIV Infection 2012. Recommendations of the International Antiviral Society-USA Panel. https://www.iasusa.org/content/antiretroviral-treatment-adult-hiv-infection-0
- The European AIDS Clinical Society (EACS). European Guidelines for treatment of HIV infected adults in Europe. Version 6.1 (dated November 2012). http://www. europeanaidsclinicalsociety.org/images/stories/EAC S -Pdf/ EacsGuidelines-v6.1-2edition.pdf.
- Williams I., Churchill D., Anderson J. et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012; 13 (Suppl 2): 1-85.
- Contreras-Hernandez I., Becker D., Chancellor J. et al. Cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals in Mexico. Value in Health 2010; 13(8): 903-914.
- Kuhne F., Chancellor J., Mollon P. et al. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals. HIV Clinical Trials 2010; 11(2): 80-99.
- Elbasha E.E., Szucs T., Chaudhary M.A. et al. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland. HIV Clinical Trials 2009; 10(4): 233-253.
- Moeremans K., Annemans L., Lothgren M. et al. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK. PharmacoEconomics 2010; 28(Suppl 1): 107-128.
- Sax P.E., Losina E., Weinstein M.C. et al. Cost-effectiveness of enfuvirtide in treatment-experienced patients with advanced HIV disease. Journal of Acquired Immune Deficiency Syndromes 2005; 39(1): 69-77.
- Mauskopf J., Brogan A.J., Talbird S.E., Martin S. Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1 infection. AIDS 2012; 26(3): 355-364.
- Hill A.M., Cho M., Mrus J.M. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients. AIDS Rev. 2011; 13(1): 41-48.
- Despiegel N., Kuehne F., Martin M., Shelbaya A. Economic modeling in HIV for maraviroc in France in treatment experienced patients. Results from the ARAMIS 2011 model. Retrovirology 2012; 9(Suppl 1): 60.
- Bucher H.C., Guyatt H.G., Griffith L.E et al. The Results of Direct and Indirect Treatment Comparisons in MetaAnalysis of Randomized Controlled Trials. J. Clin. Epidemiol. 1997; 50(6): 683-691.
- Горяйнов С.В., Реброва О.Ю. Непрямые сравнения в оценке медицинских технологий. Медицинские технологии. Оценка и выбор 2011; 3(5): 9-12.
- Salanti G. Indirect and mixed-treatment comparison, network, or multiple treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res. Syn. Meth. 2012; 3: 80-97.
- Gulick R.M., Lalezari J., Goodrich J. et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N. Engl. J. Med. 2008; 359(14): 1429-1441.
- Steigbigel R.T., Cooper D.A., Kumar P.N. et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 2008; 359(4): 339-354.
- Nelson M., Arast6h K., Clotet B. et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J. Acquir. Immune Defic. Syndr. 2005; 40(4): 404-412.
- Katlama C., Haubrich R., Lalezari J. et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23(17): 2289-2300.
- Clotet B., Bellos N., Molina J.M. et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007; 369(9568): 1169-1178.
- Trottier B., Walmsley S., Reynes J. et al. Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J. Acquir. Immune Defic. Syndr. 2005; 40(4): 413-421.
- Hardy W.D., Gulick R.M., Mayer H. et al. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2. J. Acquir. Immune Defic. Syndr. 2010; 55: 558-564.
- Gulick R., Fatkenheuer G., Burnside R. et al. Five-year safety evaluation of maraviroc in HIV-1-infected, treatment-experienced patients. Abstract TUPE029, XIX IAC, Washington DC, July 22-27 2012. http://pag.aids2012.org/ abstracts. aspx?aid= 19743.
- Steigbigel R.T., Cooper D.A., Teppler H. et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials. Clin. Infect. Dis. 2010;.50: 605-612.
- Arast6h K., Yeni P., Pozniak A. et al. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96. Antivir. Ther. 2009; 14: 859-864.
- Katlama C., Clotet B., Mills A. et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir. Ther. 2010; 15(7): 1045-1052. doi: 10.3851/IMP1662.
- Постановление Правительства Москвы от 28 декабря 2011 г. № 661-ПП «О Территориальной программе государственных гарантий оказания гражданам Российской Федерации бесплатной медицинской помощи в городе Москве на 2012 год».
- Приказ Минздрава России от 24.12.2012 № 1511н «Об утверждении стандарта первичной медикосанитарной помощи при болезни, вызванной вирусом иммунодефицита человека (ВИЧ-инфекцией)». Зарегистрировано в Минюсте России 13.02.2013 № 27053. http://www.rosminzdrav.ru/docs/mzsr/standards/ projects/762/DOC1511.pdf.
- Ладная Н.Н. Справка по итогам мониторинга ПНП «Здоровье». Расчет объема средств, предоставляемых в 2013 г. из федерального бюджета в виде межбюджетных трансфертов бюджетам субъектов Российской Федерации на закупки антиретровирусных препаратов для профилактики и лечения лиц, инфицированных вирусами иммунодефицита человека и гепатитов В и С. Суздаль, 2012.
- Постановление Правительства РФ от 27.12.2012 № 1438 «О финансовом обеспечении закупок диагностических средств и антивирусных препаратов для профилактики, выявления, мониторинга лечения и лечения лиц, инфицированных вирусами иммунодефицита человека и гепатитов B и C».
- Pichenot M., Deuffic-Burban S., Cuzin L., Yazdanpanah Y. Efficacy of new antiretroviral drugs in treatment-experienced HIV-infected patients: a systematicreview and meta-analysis of recent randomized controlled trials. HIV Med. 2012; 13(3): 148-155.